DE602005015002D1 - Methylendipiperidinderivate - Google Patents

Methylendipiperidinderivate

Info

Publication number
DE602005015002D1
DE602005015002D1 DE602005015002T DE602005015002T DE602005015002D1 DE 602005015002 D1 DE602005015002 D1 DE 602005015002D1 DE 602005015002 T DE602005015002 T DE 602005015002T DE 602005015002 T DE602005015002 T DE 602005015002T DE 602005015002 D1 DE602005015002 D1 DE 602005015002D1
Authority
DE
Germany
Prior art keywords
methylendipiperidinderivate
neurological
processes
preparation
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005015002T
Other languages
German (de)
English (en)
Inventor
Gordon Bruton
Vicky Johnstone
Barry Sidney Orlek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE602005015002D1 publication Critical patent/DE602005015002D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Indole Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
DE602005015002T 2004-09-17 2005-09-16 Methylendipiperidinderivate Expired - Lifetime DE602005015002D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0420831A GB0420831D0 (en) 2004-09-17 2004-09-17 Novel compounds
PCT/EP2005/010169 WO2006029906A1 (en) 2004-09-17 2005-09-16 Methylene dipiperidine derivatives

Publications (1)

Publication Number Publication Date
DE602005015002D1 true DE602005015002D1 (de) 2009-07-30

Family

ID=33306857

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005015002T Expired - Lifetime DE602005015002D1 (de) 2004-09-17 2005-09-16 Methylendipiperidinderivate

Country Status (8)

Country Link
US (1) US7638631B2 (enExample)
EP (1) EP1789410B1 (enExample)
JP (1) JP2008513405A (enExample)
AT (1) ATE433966T1 (enExample)
DE (1) DE602005015002D1 (enExample)
ES (1) ES2326182T3 (enExample)
GB (1) GB0420831D0 (enExample)
WO (1) WO2006029906A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
CN101472887A (zh) 2006-06-23 2009-07-01 艾博特公司 作为组胺h3受体调节物的环丙胺衍生物
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
CN103724328B (zh) 2008-12-19 2015-10-14 贝林格尔.英格海姆国际有限公司 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺
US9186353B2 (en) * 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
US20120028931A1 (en) * 2009-09-14 2012-02-02 Recordati Ireland Limited Heterocyclic m-glu5 antagonists
PL2513093T3 (pl) 2009-12-17 2015-03-31 Centrexion Therapeutics Corp Nowi antagoniści receptora CCR2 i ich zastosowanie
WO2011097357A1 (en) * 2010-02-04 2011-08-11 Flsmidth A/S Method for treating tailings
EP2569295B1 (en) 2010-05-12 2014-11-19 Boehringer Ingelheim International GmbH New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
JP2013526507A (ja) 2010-05-12 2013-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用
US8841313B2 (en) 2010-05-17 2014-09-23 Boehringer Ingelheim International Gmbh CCR2 antagonists and uses thereof
JP5636094B2 (ja) 2010-05-25 2014-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２受容体アンタゴニスト
EP2576538B1 (en) 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH New CCR2 antagonists
WO2012037258A1 (en) 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives
WO2013010839A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Novel and selective ccr2 antagonists
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
EP2647377A1 (en) 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease
AU2016287584B2 (en) 2015-07-02 2020-03-26 Centrexion Therapeutics Corporation (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
WO2017095758A1 (en) * 2015-12-01 2017-06-08 Merck Sharp & Dohme Corp. Homobispiperidinyl derivatives as liver x receptor beta agonists, compositions, and their use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0418071A (ja) 1990-05-11 1992-01-22 Sumitomo Pharmaceut Co Ltd ビスピペリジン誘導体
IL137517A0 (en) 1998-01-27 2001-07-24 Aventis Pharm Prod Inc Substituted oxoazaheterocyclyl factor xa inhibitors
TR200102810T2 (tr) 1999-04-01 2002-01-21 Pfizer Products Inc. Sorbitol dehidrojenaz inhibitörleri olarak aminopirimidinler
HUP0203375A3 (en) 1999-07-28 2005-03-29 Aventis Pharm Prod Inc Substituted oxoazaheterocyclyl compounds
PE20020507A1 (es) 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
EP1337271B1 (en) 2000-11-30 2004-11-03 Pfizer Products Inc. Combination of gaba agonists and sorbitol dehydrogenase inhibitors
CA2436083A1 (en) * 2001-02-08 2002-09-19 Schering Corporation Use of dual h3/m2 antagonists in the treatment of cognition deficit disorders
US6660858B2 (en) 2001-03-28 2003-12-09 Lion Bioscience Ag 2-aminobenzoxazole derivatives and combinatorial libraries thereof
US6956040B2 (en) * 2001-07-16 2005-10-18 Ranbaxy Laboratories Limited Oxazolidinone piperazinyl derivatives as potential antimicrobials
EP1444219A1 (en) * 2001-10-12 2004-08-11 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor

Also Published As

Publication number Publication date
EP1789410B1 (en) 2009-06-17
US20080108624A1 (en) 2008-05-08
ATE433966T1 (de) 2009-07-15
JP2008513405A (ja) 2008-05-01
US7638631B2 (en) 2009-12-29
EP1789410A1 (en) 2007-05-30
GB0420831D0 (en) 2004-10-20
ES2326182T3 (es) 2009-10-02
WO2006029906A1 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
ATE433966T1 (de) Methylendipiperidinderivate
ES2299896T3 (es) Derivados de benzazepina como antagonistas h3 de histamina.
TW200503713A (en) Novel compounds
TW200503710A (en) Novel compounds
TW200500344A (en) Novel compounds
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200611702A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
GB0625648D0 (en) Compounds
BRPI0518228A (pt) inibidores de cinesina mitótica e métodos de uso destes
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
TW200621716A (en) Novel compounds
TW200514781A (en) Novel compounds
GB0111186D0 (en) Novel compounds
CR9622A (es) Derivados de pirazolo[3,4-d]azepina como antagonistas de histamina h3
NO20074977L (no) Fuserte tiazolderivater med affinitet for histamin H3 receptoren
TW200611695A (en) Pyrrolopyridine derivatives
TW200611701A (en) Novel compounds
SE0401465D0 (sv) New substituted piperdines as modulators of dopamine neurotransmission
GB0320320D0 (en) Novel compounds
MX2007006754A (es) Derivados de indenilo y uso de los mismos para el tratamiento de trastornos neurologicos.
UY26426A1 (es) Nuevos compuestos
PT1853232E (pt) Forma cristalina estável de mesilato de bifeprunox, suas formas de dosagem e métodos para a sua utilização
TW200726763A (en) Novel compound
ATE524463T1 (de) 4-chromenonyl-1,4-dihydropyridincarbonitrile und ihre verwendung
TW200734335A (en) Compounds

Legal Events

Date Code Title Description
8364 No opposition during term of opposition